“Like a beautiful blossom, life unfolds for each of us, And within every EXPERIENCE lie infinite possibilities.”

References
8: REFERENCES


Aversano T, Aversano LT, Passamani E, et al, for the Atlantic Cardiovascular Patient Outcomes Research Team (C-POR). Thrombolytic therapy vs. primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002; 287: 1943-51.


Brown BG, Stewart BF, Zhao X-Q, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol 1995;76:93C-7C.


Brown BG, Zhao XQ. Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events. In: Grundy SM, ed.


Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 1995; 76: 129A-35A.


Clinical Study Report (ISU ABXIS CO., LTD: Clotinab II): A multicentre, open-label, therapeutic and exploratory trial to evaluate the safety and efficacy of platelet glycoprotein (GP) IIb/IIIa receptor blocker (Clotinab) in high-risk patients with Percutaneous Coronary Intervention, 2006.


Dewan BD, Malhotra KC, Gupta SP. Epidemiological study of coronary heart disease in rural community of Haryana. Indian Heart J 1974; 26: 68-78.


Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The Polymeal: a more natural, safer and probably less tarter (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 2004; 329: 1447-1450


Fuster V. Coronary thrombolysis: a perspective for the practicing physician. NEJM 1993; 329: 723-5.


Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ, for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. NEJM1993; 328: 685-91.


GSUTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. NEJM 1993; 329: 673-82.


ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous


Killer T 3d, Kimball JT. Tretment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967; 20457-64. (Medline)


Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S. Equivalent efficacy of a time-release form of


Anuja Shah - LM College of Pharmacy, Ahmedabad, India


References


Remedia Investigators. REMEDIA: the Randomized Evaluation of the Effect of Mechanical Reduction of Distal Embolization by Thrombus-Aspiration in Primary and Rescue Angioplasty Trial.


Simon DI, Xu H, Ortlepp S et al. 7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscle Thromb Vasc Biol. 1997; 17: 528-35.


Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol 1998; 82: 40J-6J.

Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B-9B.


The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. NEJM 1994; 330: 956-61.


The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. NEJM 1998; 338: 1488-97.


The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. NEJM 1989; 320: 618-27.


Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and


Topol EJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995; 75: 27B-33B.


---

Anuja Shah

- 189 -

L.M. College of Pharmacy, Ahmedabad, India


Wiviott et al., NEJM. 2007; 357(20):2001-15


